DexComXSWX:DXCM 90 Return-on-Tangible-Equity is 28.83% as of Mar. 2026, which is 87% above its 10-year median of 15.41. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 760 Medical Devices & Instruments companies, DexCom ranks better than 90.13% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. DexCom's annualized net income for the quarter that ended in Mar. 2026 was CHF628 Mil. DexCom's average shareholder tangible equity for the quarter that ended in Mar. 2026 was CHF2,179 Mil. Therefore, DexCom's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 28.83%.
The historical rank and industry rank for DexCom's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:DXCM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -26.9 Med: 15.41 Max: 37.26
Current: 36.53
During the past 13 years, DexCom's highest Return-on-Tangible-Equity was 37.26%. The lowest was -26.90%. And the median was 15.41%.
XSWX:DXCM's Return-on-Tangible-Equity is ranked better than 90.13% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs XSWX:DXCM: 36.53
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
DexCom Return-on-Tangible-Equity Related Terms
DexCom Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for DexCom's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:DXCM vs GEHC, STE, ZBH: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, DexCom's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where DexCom's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 28.83% mean?
DexCom (XSWX:DXCM) has a Return-on-Tangible-Equity of 28.83% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on DexCom and its competitors. This is 87% above median its historical median of 15.41. According to the industry distribution chart, DexCom ranks #75 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 9.9%.
Is DexCom's Return-on-Tangible-Equity too high?
DexCom's current Return-on-Tangible-Equity of 28.83% is 87% above median its 10-year median of 15.41. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.12. DexCom's value of 28.83% is 600.6% above this industry median. Based on the distribution chart, DexCom ranks #75 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Return-on-Tangible-Equity compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #75 out of 760 companies for Return-on-Tangible-Equity. This places DexCom in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.12. DexCom's value of 28.83% is 600.6% above this benchmark. While the company's 10-year median is 15.41 vs. the industry median of 4.12, DexCom has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current Return-on-Tangible-Equity of 28.83% is 600.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current Return-on-Tangible-Equity is 28.83%, which is 87% above median its own 10-year median of 15.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Return-on-Tangible-Equity of 28.83%. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current Return-on-Tangible-Equity is 28.83%, which is 87% above median its 10-year median of 15.41 and 600.6% above the Medical Devices & Instruments industry median of 4.12. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Return-on-Tangible-Equity is 28.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (XSWX:DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.
Key valuation signals for XSWX:DXCM:
Return-on-Tangible-Equity: 28.83% (87% above median its 10-year median of 15.41)
GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
Industry Position: 600.6% above the Medical Devices & Instruments median (#75 of 760)
No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for XSWX:DXCM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DXCM has been successfully added to your 
